We have located links that may give you full text access.
Vascular and metabolic effects of ipragliflozin versus sitagliptin in type 2 diabetes treated with sulfonylurea and metformin: IVS study.
Diabetes, Obesity & Metabolism 2023 March 19
OBJECTIVE: In patients with type 2 diabetes who were inadequately controlled with metformin and sulfonylurea, we compared the glucose-lowering efficacy, cardiometabolic parameters, and safety of two drugs, ipragliflozin, a SGLT-2 inhibitor, and sitagliptin, a DPP-4 inhibitor.
RESEARCH DESIGN AND METHODS: Patients with 7.5%-9.0% glycated hemoglobin (HbA1c) treated with metformin and sulfonylurea were randomly assigned to ipragliflozin (50 mg, n = 70) or sitagliptin (100 mg, n = 70) therapy for 24 weeks. Measures of glycemic control, fatty liver indices, other metabolic parameters, and subclinical atherosclerosis were compared by a paired t-test before and after 24 weeks of treatment.
RESULTS: Mean HbA1c levels decreased from 8.5% to 7.5% in the ipragliflozin group and from 8.5% to 7.8% in the sitagliptin group, resulting in a 0.34% between-group difference (95% confidence interval, 0.10%-0.43%, P = 0.088). Fasting and postprandial 2-hour glucose levels also showed a similar trend, with a greater reduction with ipragliflozin therapy. An increase of over 70% in ketone levels and a decrease in whole body and abdominal fat masses were observed with ipragliflozin treatment. Fatty liver indices also improved with ipragliflozin treatment. Despite no difference in carotid intima-media thickness and ankle-brachial index, ipragliflozin therapy improved flow-mediated vasodilation, reflecting endothelial function, while sitagliptin did not. The safety profile did not differ between the two groups.
CONCLUSIONS: Ipragliflozin add-on therapy can be a viable option for better glycemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulfonylurea. This article is protected by copyright. All rights reserved.
RESEARCH DESIGN AND METHODS: Patients with 7.5%-9.0% glycated hemoglobin (HbA1c) treated with metformin and sulfonylurea were randomly assigned to ipragliflozin (50 mg, n = 70) or sitagliptin (100 mg, n = 70) therapy for 24 weeks. Measures of glycemic control, fatty liver indices, other metabolic parameters, and subclinical atherosclerosis were compared by a paired t-test before and after 24 weeks of treatment.
RESULTS: Mean HbA1c levels decreased from 8.5% to 7.5% in the ipragliflozin group and from 8.5% to 7.8% in the sitagliptin group, resulting in a 0.34% between-group difference (95% confidence interval, 0.10%-0.43%, P = 0.088). Fasting and postprandial 2-hour glucose levels also showed a similar trend, with a greater reduction with ipragliflozin therapy. An increase of over 70% in ketone levels and a decrease in whole body and abdominal fat masses were observed with ipragliflozin treatment. Fatty liver indices also improved with ipragliflozin treatment. Despite no difference in carotid intima-media thickness and ankle-brachial index, ipragliflozin therapy improved flow-mediated vasodilation, reflecting endothelial function, while sitagliptin did not. The safety profile did not differ between the two groups.
CONCLUSIONS: Ipragliflozin add-on therapy can be a viable option for better glycemic control with multiple vascular and metabolic benefits in patients with type 2 diabetes who are inadequately controlled with metformin and sulfonylurea. This article is protected by copyright. All rights reserved.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app